Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23288616 | 0.82 | KCNH2 (0.45) | LMNATHRBKCNH2TP53RXFP1 | |
| SCHEMBL23268370 | 0.76 | HASPIN (0.47) | KCNH2 | |
| SCHEMBL627773 | 0.75 | MAPT (0.43) | HRH3LMNATHRBTP53POLB | |
| SCHEMBL626210 | 0.73 | IRAK1 (0.47) | LMNATHRBTP53RXFP1 | |
| SCHEMBL624034 | 0.72 | LMNA (0.48) | LMNATHRBTP53RXFP1POLB | |
| SCHEMBL627054 | 0.72 | KDM4E (0.48) | LMNATHRBTP53RXFP1POLB | |
| SCHEMBL23268395 | 0.72 | KCNH2 (0.38) | LMNATHRBKCNH2TP53RXFP1 | |
| SCHEMBL23268324 | 0.72 | KCNH2 (0.36) | LMNATHRBKCNH2 | |
| SCHEMBL23268317 | 0.72 | KCNH2 (0.36) | LMNATHRBKCNH2 | |
| SCHEMBL627192 | 0.70 | BTK (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |